Conflicting evidence exists as to whether TRAIL levels differ significantly between subtypes, some reporting no change [34,36]; however, one study identified that circulating TRAIL levels were lower in patients with SAO [38]; low levels persisted for at least three months after the onset of stroke. This evidence concerns the gene TNFSF10 and Stroke.